

References

- Arredondo, M., Munoz, P., Mura, C. V., & Nunez, M. T. (2003). DMT1, a physiologically relevant apical Cu¹⁺ transporter of intestinal cells. *American Journal of Physiology. Cell Physiology*, 284(6), C1525-30. <https://doi.org/10.1152/ajpcell.00480.2002>
- Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O'Flaherty, J. D., ... O'Byrne, K. J. (2013). Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. *PLoS ONE*, 8(1). <https://doi.org/10.1371/journal.pone.0054193>
- Basu, A., & Krishnamurthy, S. (2010). Cellular responses to cisplatin-induced DNA damage. *Journal of Nucleic Acids*, 2010. <https://doi.org/10.4061/2010/201367>
- Brewer, G. J. (2009). The use of copper-lowering therapy with tetrathiomolybdate in medicine. *Expert Opinion on Investigational Drugs*, 18(1), 89–97. <https://doi.org/10.1517/13543780802621859>
- Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., & Cox, D. W. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nature Genetics*, 5(4), 327–337. <https://doi.org/10.1038/ng1293-327>
- Camakaris, J., Voskoboinik, I., & Mercer, J. F. (1999). Molecular mechanisms of copper homeostasis. *Biochemical and Biophysical Research Communications*, 261(2), 225–232. <https://doi.org/10.1006/bbrc.1999.1073>
- Chao, C. C. (1994). Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair. *Molecular Pharmacology*, 45(6), 1137–1144. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/8022407>
- Chen, C.-C., Chen, L.-T., Tsou, T.-C., Pan, W.-Y., Kuo, C.-C., Liu, J.-F., ... Chang, J.-Y. (2007). Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. *British Journal of Cancer*, 97(3), 334–344. <https://doi.org/10.1038/sj.bjc.6603866>
- Chen, S.-J., Kuo, C.-C., Pan, H.-Y., Tsou, T.-C., Yeh, S.-C., & Chang, J.-Y. (2015). Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. *Biochemical Pharmacology*, 95(1), 28–37. <https://doi.org/10.1016/j.bcp.2015.03.006>
- Chisholm, C. L., Wang, H., Wong, A. H.-H., Vazquez-Ortiz, G., Chen, W., Xu, X., & Deng, C.-X. (2016). Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. *Oncotarget*, 7(51), 84439–84452. <https://doi.org/10.18632/oncotarget.12992>
- Choi, K.-C., Kim, S.-H., Ha, J.-Y., Kim, S.-T., & Son, J. H. (2010). A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. *Journal of Neurochemistry*, 112(2), 366–376. <https://doi.org/10.1111/j.1471-4159.2009.06463.x>
- Crul, M., van Waardenburg, R. C. A. M., Beijnen, J. H., & Schellens, J. H. M. (2002). DNA-based drug interactions of cisplatin. *Cancer Treatment Reviews*, 28(6), 291–303. [https://doi.org/10.1016/S0305-7372\(02\)00093-2](https://doi.org/10.1016/S0305-7372(02)00093-2)
- Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015). Targeting copper in cancer therapy: "Copper That Cancer". *Metalomics : Integrated Biometal Science*, 7(11), 1459–1476. <https://doi.org/10.1039/c5mt00149h>
- DiDonato, M., & Sarkar, B. (1997). Copper transport and its alterations in Menkes and Wilson diseases. *Biochimica et Biophysica Acta*, 1360(1), 3–16. [https://doi.org/10.1016/s0925-4439\(96\)00064-6](https://doi.org/10.1016/s0925-4439(96)00064-6)
- Dolgova, N. V., Nokhrin, S., Yu, C. H., George, G. N., & Dmitriev, O. Y. (2013). Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification.

- The Biochemical Journal*, 454(1), 147–156. <https://doi.org/10.1042/BJ20121656>
- Fayngerts, S. A., Wu, J., Oxley, C. L., Liu, X., Vourekas, A., Cathopoulis, T., ... Chen, Y. H. (2014). TIPE3 is the transfer protein of lipid second messengers that promote cancer. *Cancer Cell*, 26(4), 465–478. <https://doi.org/10.1016/j.ccr.2014.07.025>
- Fu, S., Naing, A., Fu, C., Kuo, M. T., & Kurzrock, R. (2012). Overcoming platinum resistance through the use of a copper-lowering agent. *Molecular Cancer Therapeutics*, 11(6), 1221–1225. <https://doi.org/10.1158/1535-7163.MCT-11-0864>
- Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., ... Kroemer, G. (2012). Molecular mechanisms of cisplatin resistance. *Oncogene*, 31(15), 1869–1883. <https://doi.org/10.1038/onc.2011.384>
- Ganapathy-kanniappan, S., & Geschwind, J.-F. (2013). Tumor glycolysis as a target for cancer therapy : *Molecular Cancer*, 12(1), 1–11. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223729/pdf/1476-4598-12-152.pdf>
- Gasque, K. C. D. S., Al-Ahj, L. P., Oliveira, R. C., & Magalhães, A. C. (2014). Cell density and solvent are critical parameters affecting formazan evaluation in MTT assay. *Brazilian Archives of Biology and Technology*, 57(3), 381–385. <https://doi.org/10.1590/S1516-89132014005000007>
- Goldsmith, J. R., Fayngerts, S., & Chen, Y. H. (2017). Regulation of inflammation and tumorigenesis by the TIPE family of phospholipid transfer proteins. *Cellular & Molecular Immunology*, 14(6), 482–487. <https://doi.org/10.1038/cmi.2017.4>
- González, B., Mas, A., Beltran, G., Cullen, P. J., & Torija, M. J. (2017). Role of Mitochondrial Retrograde Pathway in Regulating Ethanol-Inducible Filamentous Growth in Yeast . *Frontiers in Physiology* . Retrieved from <https://www.frontiersin.org/article/10.3389/fphys.2017.00148>
- Goodman, V. L., Brewer, G. J., & Merajver, S. D. (2004). Copper deficiency as an anti-cancer strategy. *Endocrine-Related Cancer*, 11(2), 255–263.
- Guaragnella, N., Giannattasio, S., & Moro, L. (2014). Mitochondrial dysfunction in cancer chemoresistance. *Biochemical Pharmacology*, 92(1), 62–72. <https://doi.org/10.1016/j.bcp.2014.07.027>
- Gupta, A., & Lutsenko, S. (2009). Human copper transporters: mechanism, role in human diseases and therapeutic potential. *Future Medicinal Chemistry*, 1(6), 1125–1142. <https://doi.org/10.4155/fmc.09.84>
- Hamza, I., Schaefer, M., Klomp, L. W. J., & Gitlin, J. D. (1999). Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. *Proceedings of the National Academy of Sciences*, 96(23), 13363 LP – 13368. <https://doi.org/10.1073/pnas.96.23.13363>
- Holzer, A. K., Katano, K., Klomp, L. W. J., & Howell, S. B. (2004). Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 10(19), 6744–6749. <https://doi.org/10.1158/1078-0432.CCR-04-0748>
- Inoue, Y., Matsumoto, H., Yamada, S., Kawai, K., Suemizu, H., Gika, M., ... Iwazaki, M. (2010). ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer. *Oncology Letters*, 1(2), 279–282. https://doi.org/10.3892/ol_00000049
- Inoue, Y., Matsumoto, H., Yamada, S., Kawai, K., Suemizu, H., Gika, M., ... Nakamura, M. (2010). Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer. *Oncology Letters*, 1(5), 837–840. https://doi.org/10.3892/ol_00000147
- Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. *Proceedings of the National Academy of Sciences of the United States of America*, 99(22), 14298–14302. <https://doi.org/10.1073/pnas.162491399>
- Jo, H. Y., Kim, Y., Park, H. W., Moon, H. E., Bae, S., Kim, J., ... Paek, S. H. (2015). The Unreliability of MTT Assay in the Cytotoxic Test of Primary Cultured Glioblastoma Cells. *Experimental Neurobiology*, 24(3), 235. <https://doi.org/10.5607/en.2015.24.3.235>

- Kalayda, G. V., Wagner, C. H., Buss, I., Reedijk, J., & Jaehde, U. (2008). Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. *BMC Cancer*, 8, 175. <https://doi.org/10.1186/1471-2407-8-175>
- Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M., ... Howell, S. B. (2002). Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. *Cancer Research*, 62(22), 6559–6565.
- Katano, K., Safaei, R., Samimi, G., Holzer, A., Rochdi, M., & Howell, S. B. (2003). The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. *Molecular Pharmacology*, 64(2), 466–473. <https://doi.org/10.1124/mol.64.2.466>
- Katano, K., Safaei, R., Samimi, G., Holzer, A., Tomioka, M., Goodman, M., & Howell, S. B. (2004). Confocal Microscopic Analysis of the Interaction between Cisplatin and the Copper Transporter ATP7B in Human Ovarian Carcinoma Cells. *Clinical Cancer Research*, 10(13), 4578 LP – 4588. <https://doi.org/10.1158/1078-0432.CCR-03-0689>
- Klomp, A. E. M., Tops, B. B. J., Van Denberg, I. E. T., Berger, R., & Klomp, L. W. J. (2002). Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). *The Biochemical Journal*, 364(Pt 2), 497–505. <https://doi.org/10.1042/BJ20011803>
- Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., ... Akiyama, S. I. (2000). Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. *Cancer Research*, 60(5), 1312–1316.
- Kumar, D., Whiteside, T. L., & Kasid, U. (2000). Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein. *The Journal of Biological Chemistry*, 275(4), 2973–2978. <https://doi.org/10.1074/jbc.275.4.2973>
- Kumar, Deepak, Gokhale, P., Broustas, C., Chakravarty, D., Ahmad, I., & Kasid, U. (2004). Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. *Oncogene*, 23(2), 612–616. <https://doi.org/10.1038/sj.onc.1207123>
- Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007). The roles of copper transporters in cisplatin resistance. *Cancer Metastasis Reviews*, 26(1), 71–83. <https://doi.org/10.1007/s10555-007-9045-3>
- Kuo, M. T., Fu, S., Savaraj, N., & Chen, H. H. W. (2012). Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. *Cancer Research*, 72(18), 4616–4621. <https://doi.org/10.1158/0008-5472.CAN-12-0888>
- Kuo, Y. M., Zhou, B., Cosco, D., & Gitschier, J. (2001). The copper transporter CTR1 provides an essential function in mammalian embryonic development. *Proceedings of the National Academy of Sciences of the United States of America*, 98(12), 6836–6841. <https://doi.org/10.1073/pnas.111057298>
- Lee, J., Prohaska, J. R., & Thiele, D. J. (2001). Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. *Proceedings of the National Academy of Sciences of the United States of America*, 98(12), 6842–6847. <https://doi.org/10.1073/pnas.111058698>
- Lee, Jaekwon, Petris, M. J., & Thiele, D. J. (2002). Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. *The Journal of Biological Chemistry*, 277(43), 40253–40259. <https://doi.org/10.1074/jbc.M208002200>
- Leonhardt, K., Gebhardt, R., Mössner, J., Lutsenko, S., & Huster, D. (2009). Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. *The Journal of Biological Chemistry*, 284(12), 7793–7802. <https://doi.org/10.1074/jbc.M805145200>
- Li, Y., Yin, J., & Liu, Z. (2018). Critical Review Copper Efflux Transporters ATP7A and ATP7B : Novel Biomarkers for Platinum Drug Resistance and Targets for Therapy. *International Union of Biochemistry and Molecular Biology*, 70(3), 183–191. <https://doi.org/10.1002/iub.1722>

- Li, Z., Qiu, M., Zeng, Z., Luo, H., Wu, W., Wang, F., ... Xu, R. (2012). Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). *Journal of Translational Medicine*, 10, 21. <https://doi.org/10.1186/1479-5876-10-21>
- Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002). The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae. *Molecular Pharmacology*, 62(5), 1154 LP – 1159. <https://doi.org/10.1124/mol.62.5.1154>
- Liu, T., Gao, H., Yang, M., Zhao, T., Liu, Y., & Lou, G. (2014). Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. *Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine*, 35(6), 5805–5814. <https://doi.org/10.1007/s13277-014-1770-y>
- Liu, T., Xia, B., Lu, Y., Xu, Y., & Lou, G. (2014). TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction. *Human Pathology*, 45(6), 1251–1257. <https://doi.org/10.1016/j.humpath.2014.02.005>
- Lou, Y., & Liu, S. (2011). The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. *Molecular Immunology*, 49(1–2), 4–7. <https://doi.org/10.1016/j.molimm.2011.08.006>
- Low, S. Y., Tan, B. S., Choo, H. L., Tiong, K. H., Khoo, A. S.-B., & Leong, C.-O. (2012). Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. *Cancer Letters*, 314(2), 166–175. <https://doi.org/10.1016/j.canlet.2011.09.025>
- Lutsenko, S., & Petris, M. J. (2003). Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and cell biological approaches. *The Journal of Membrane Biology*, 191(1), 1–12. <https://doi.org/10.1007/s00232-002-1040-6>
- Mangala, L. S., Zuzel, V., Schmandt, R., Leshane, E. S., Halder, J. B., Armaiz-Pena, G. N., ... Sood, A. K. (2009). Therapeutic Targeting of ATP7B in Ovarian Carcinoma. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 15(11), 3770–3780. <https://doi.org/10.1158/1078-0432.CCR-08-2306>
- Martinez-Balibrea, E., Martinez-Cardus, A., Musulen, E., Gines, A., Manzano, J. L., Aranda, E., ... Abad, A. (2009). Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. *International Journal of Cancer*, 124(12), 2905–2910. <https://doi.org/10.1002/ijc.24273>
- Minagawa, Y., Kigawa, J., Itamochi, H., & Kanamori, Y. (1999). Cisplatin-resistant HeLa Cells Are Resistant to Apoptosis via p53-dependent and -independent Pathways, (December), 1373–1379.
- Miyashita, H., Nitta, Y., Mori, S., Kanzaki, A., Nakayama, K., Terada, K., ... Takebayashi, Y. (2003). Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. *Oral Oncology*, 39(2), 157–162.
- Nikounezhad, N. (2016). Generation of Cisplatin-Resistant Ovarian Cancer Cell Lines. *Iranian Journal of Pharmaceutical Sciences*, 12(1), 11–20.
- Paridah, M. ., Moradbak, A., Mohamed, A. ., Owolabi, F. abdulwahab taiwo, Asniza, M., & Abdul Khalid, S. H. . (2016). In vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages. *InTech, i(tourism)*, 13. <https://doi.org/http://dx.doi.org/10.5772/57353>
- Patel, S., Wang, F. H., Whiteside, T. L., & Kasid, U. (1997). Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. *Oral Oncology*, 33(3), 197–203.
- Petris, M J, Strausak, D., & Mercer, J. F. (2000). The Menkes copper transporter is required for the activation of tyrosinase. *Human Molecular Genetics*, 9(19), 2845–2851. <https://doi.org/10.1093/hmg/9.19.2845>
- Petris, Michael J, Smith, K., Lee, J., & Thiele, D. J. (2003). Copper-stimulated endocytosis and

- degradation of the human copper transporter, hCtr1. *The Journal of Biological Chemistry*, 278(11), 9639–9646. <https://doi.org/10.1074/jbc.M209455200>
- Plasencia, C., Martínez-Balibrea, E., Martinez-Cardus, A., Quinn, D., Abad, A., & Neamati, N. (2006). Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. *International journal of oncology* (Vol. 29). <https://doi.org/10.3892/ijo.29.1.225>
- Prohaska, J. R., & Gybina, A. A. (2004). Intracellular copper transport in mammals. *The Journal of Nutrition*, 134(5), 1003–1006. <https://doi.org/10.1093/jn/134.5.1003>
- Rees, E. M., Lee, J., & Thiele, D. J. (2004). Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter. *The Journal of Biological Chemistry*, 279(52), 54221–54229. <https://doi.org/10.1074/jbc.M411669200>
- Safaei, R. (2006). Role of copper transporters in the uptake and efflux of platinum containing drugs. *Cancer Letters*, 234(1), 34–39. <https://doi.org/10.1016/j.canlet.2005.07.046>
- Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004). The role of copper transporters in the development of resistance to Pt drugs. *Journal of Inorganic Biochemistry*, 98(10), 1607–1613. <https://doi.org/10.1016/j.jinorgbio.2004.05.006>
- Safaei, R., & Howell, S. B. (2005). Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. *Critical Reviews in Oncology/Hematology*, 53(1), 13–23. <https://doi.org/10.1016/j.critrevonc.2004.09.007>
- Safaei, R., Katano, K., Samimi, G., Naerdemann, W., Stevenson, J. L., Rochdi, M., & Howell, S. B. (2004). Cross-resistance to cisplatin in cells with acquired resistance to copper. *Cancer Chemotherapy and Pharmacology*, 53(3), 239–246. <https://doi.org/10.1007/s00280-003-0736-3>
- Safaei, R., Otani, S., Larson, B. J., Rasmussen, M. L., & Howell, S. B. (2008). Transport of cisplatin by the copper efflux transporter ATP7B. *Molecular Pharmacology*, 73(2), 461–468. <https://doi.org/10.1124/mol.107.040980>
- Samimi, G., Katano, K., Holzer, A. K., Safaei, R., & Howell, S. B. (2004). Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. *Molecular Pharmacology*, 66(1), 25–32. <https://doi.org/10.1124/mol.66.1.25>
- Samimi, G., Varki, N. M., Wilczynski, S., Safaei, R., Alberts, D. S., & Howell, S. B. (2003). Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 9(16 Pt 1), 5853–5859.
- Shaloam, D., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*, 740(1), 364–378. <https://doi.org/10.1016/j.ejphar.2014.07.025.Cisplatin>
- Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012). Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. *Pharmacological Reviews*, 64(3), 706–721. <https://doi.org/10.1124/pr.111.005637>
- Shi, T.-Y., Cheng, X., Yu, K.-D., Sun, M.-H., Shao, Z.-M., Wang, M.-Y., ... Wei, Q. (2013). Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes . *Carcinogenesis*, 34(4), 770–778. <https://doi.org/10.1093/carcin/bgt001>
- Siddik, Z. H. (2003). Cisplatin: Mode of cytotoxic action and molecular basis of resistance. *Oncogene*, 22(47 REV. ISS. 6), 7265–7279. <https://doi.org/10.1038/sj.onc.1206933>
- Stockert, J. C., Blázquez-Castro, A., Cañete, M., Horobin, R. W., & Villanueva, Á. (2012). MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. *Acta Histochemica*, 114(8), 785–796. <https://doi.org/10.1016/j.acthis.2012.01.006>
- Stordal, B., & Davey, M. (2007). Understanding cisplatin resistance using cellular models. *IUBMB Life*, 59(11), 696–699. <https://doi.org/10.1080/15216540701636287>
- Sun, H., Gong, S., Carmody, R. J., Hilliard, A., Li, L., Sun, J., ... Chen, Y. H. (2008). TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. *Cell*, 133(3),

- 415–426. <https://doi.org/10.1016/j.cell.2008.03.026>
- Takahashi, Y., Tsuruta, S., Honda, A., Fujiwara, Y., Satoh, M., & Yasutake, A. (2012). Effect of dental amalgam on gene expression profiles in rat cerebrum, cerebellum, liver and kidney. *The Journal of Toxicological Sciences*, 37(3), 663–666.
- Wosikowski, K., Silverman, J. A., Bishop, P., Mendelsohn, J., & Bates, S. E. (2000). Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. *Biochimica et Biophysica Acta*, 1497(2), 215–226.
[https://doi.org/10.1016/s0167-4889\(00\)00062-8](https://doi.org/10.1016/s0167-4889(00)00062-8)
- Wu, S., Li, W., Wu, Z., Cheng, T., Wang, P., Li, N., ... Chai, L. (2019). TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis. *Oncology Letters*, 4667–4674. <https://doi.org/10.3892/ol.2019.10076>
- Xing, Y., Liu, Y., Liu, T., Meng, Q., Lu, H., Liu, W., ... Cai, L. (2018). TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway. *Cell Communication and Signaling*, 16(1), 43. <https://doi.org/10.1186/s12964-018-0254-x>
- Xu, W., Cai, B., Chen, J. L., Li, L. X., Zhang, J. R., Sun, Y. Y., & Wan, X. P. (2008). ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl. *International Journal of Gynecologic Cancer*, 18(4), 718 LP – 722.
<https://doi.org/10.1136/ijgc-00009577-200807000-00016>
- Yang, M., Zhao, Q., Wang, X., Liu, T., Yao, G., Lou, C., & Zhang, Y. (2014). TNFAIP8 overexpression is associated with lymph node metastasis and poor prognosis in intestinal-type gastric adenocarcinoma. *Histopathology*, 65(4), 517–526. <https://doi.org/10.1111/his.12413>
- Yang, T.-M., Barbone, D., Fennell, D. A., & Broaddus, V. C. (2009). Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. *American Journal of Respiratory Cell and Molecular Biology*, 41(1), 14–23. <https://doi.org/10.1165/rcmb.2008-0320OC>
- You, Z., Ouyang, H., Lopatin, D., Polver, P. J., & Wang, C. Y. (2001). Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. *The Journal of Biological Chemistry*, 276(28), 26398–26404. <https://doi.org/10.1074/jbc.M102464200>
- Zhang, Lei, Liu, R., Luan, Y., & Yao, Y. (2018). Tumor Necrosis Factor- α Induced Protein 8 : Pathophysiology , Clinical Significance , and Regulatory Mechanism, 14.
<https://doi.org/10.7150/ijbs.23268>
- Zhang, Ling-juan, Liu, X., Gafken, P. R., Kioussi, C., & Leid, M. (2009). A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8 (TNFAIP8). *The Journal of Biological Chemistry*, 284(10), 6156–6168. <https://doi.org/10.1074/jbc.M807713200>
- Zheng, R., Jia, J., Li, Z., Qiu, M., & Chen, J. (2016). The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC). *Journal of Cancer*, 7(14), 2085–2092.
<https://doi.org/10.7150/jca.16117>
- Zhou, Y., Ling, X.-L., Li, S.-W., Li, X.-Q., & Yan, B. (2010). Establishment of a human hepatoma multidrug resistant cell line in vitro. *World Journal of Gastroenterology*, 16(18), 2291–2297.
<https://doi.org/10.3748/wjg.v16.i18.2291>
- Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016). Molecular mechanisms of cisplatin resistance in cervical cancer. *Drug Design, Development and Therapy*, 10, 1885.
<https://doi.org/10.2147/DDDT.S106412>